Tess Oram
Patent Agent
Tess B. Oram, Ph.D., is a patent agent in the Washington, D.C., office of Wilson Sonsini Goodrich & Rosati, where she is a member of the patents and innovations group. Tess specializes in patent prosecution and counseling across a range of multidisciplinary fields, including neuropharmacology and neurophysiology, bioinformatics, CRISPR gene editing and RNA therapies, molecular diagnostics, antibody and protein therapeutics, and machine learning.
Before joining Wilson Sonsini, Tess investigated the neural mechanisms of complex sensorimotor behaviors, utilizing a combination of quantitative/statistical behavioral analysis and advanced genetic and electrophysiological techniques. Tess’s scientific investigations were conducted at the Howard Hughes Medical Institute | Janelia Research Campus and the Weizmann Institute of Science. She has co-authored over 10 peer-reviewed scientific articles.
Experience
Tess B. Oram, Ph.D., is a patent agent in the Washington, D.C., office of Wilson Sonsini Goodrich & Rosati, where she is a member of the patents and innovations group. Tess specializes in patent prosecution and counseling across a range of multidisciplinary fields, including neuropharmacology and neurophysiology, bioinformatics, CRISPR gene editing and RNA therapies, molecular diagnostics, antibody and protein therapeutics, and machine learning.
Before joining Wilson Sonsini, Tess investigated the neural mechanisms of complex sensorimotor behaviors, utilizing a combination of quantitative/statistical behavioral analysis and advanced genetic and electrophysiological techniques. Tess’s scientific investigations were conducted at the Howard Hughes Medical Institute | Janelia Research Campus and the Weizmann Institute of Science. She has co-authored over 10 peer-reviewed scientific articles.
Education
- Postdoctoral Associate, Howard Hughes Medical Institute | Janelia Research Campus
- Ph.D., Weizmann Institute of ScienceDepartment of Neuroscience
- M.Sc., Life Sciences, Weizmann Institute of ScienceDepartment of Neuroscience
- B.Sc., Neuroscience with Honors, Brown University
Admissions
- U.S. Patent and Trademark Office
Credentials
Education
- Postdoctoral Associate, Howard Hughes Medical Institute | Janelia Research Campus
- Ph.D., Weizmann Institute of ScienceDepartment of Neuroscience
- M.Sc., Life Sciences, Weizmann Institute of ScienceDepartment of Neuroscience
- B.Sc., Neuroscience with Honors, Brown University
Admissions
- U.S. Patent and Trademark Office
Select Publications
- Co-author with A. Tenzer, I. Saraf-Sinik, O. Yizhar, and E. Ahissar, “Co-Coding of Head and Whisker Movements by Both VPM and POm Thalamic Neurons,”15(1) Nature Communications 5883, 2024
- Co-author with G.M. Card, “Context-Dependent Control of Behavior in Drosophila,” 73 Current Opinion in Neurobiology 102523, 2022
- Co-author with S. El-Boustani, B.S. Sermet, G. Foustoukos, O. Yizhar, and C.C.H. Petersen, “Anatomically and Functionally Distinct Thalamocortical Inputs to Primary and Secondary Mouse Whisker Somatosensory Cortices,” 11(1) Nature Communications 3342, 2020
- Co-author with A. Wallach, D. Deutsch, and E. Ahissar, “Predictive Whisker Kinematics Reveal Context-Dependent Sensorimotor Strategies,” 18(5) PLoS e3000571, 2020
- Co-author with T.A. Zolnik, J. Ledderose, M. Toumazou, T. Trimbuch, C. Rosenmund, B.J. Eickholt, R.N.S. Sachdev, and M.E. Larkum, “Layer 6b is Driven by Intracortical Long-Range Projection Neurons,” 30(10) Cell Reports 3492-3505.e5, 2020
- Co-author with B.S. Sermet, P. Truschow, M. Feyerabend, J.M. Mayrhofer, O. Yizhar, J.F. Staiger, and C.C.H. Petersen, “Pathway-, Layer-and Cell-Type-Specific Thalamic Input to Mouse Barrel Cortex,” 8 eLife e52665, 2019
- Co-author with D. Sherman, D. Harel, and E. Ahissar, “Attention Robustly Gates a Closed-Loop Touch Reflex,” 27(12) Current Biology 1836-1843.e7, 2017
- Co-author with E. Ahissar, “Thalamic Relay or Cortico-Thalamic Processing? Old Question, New Answers,” 25(4) Cerebral Cortex 845-848, 2015
- Co-author with D. Sherman, D. Deutsch, G. Gordon, E. Ahissar, D. Harel, “Tactile Modulation of Whisking via the Brainstem Loop: Statechart Modeling and Experimental Validation,” 8(11) PLoS One e79831, 2013
Insights
Select Publications
- Co-author with A. Tenzer, I. Saraf-Sinik, O. Yizhar, and E. Ahissar, “Co-Coding of Head and Whisker Movements by Both VPM and POm Thalamic Neurons,”15(1) Nature Communications 5883, 2024
- Co-author with G.M. Card, “Context-Dependent Control of Behavior in Drosophila,” 73 Current Opinion in Neurobiology 102523, 2022
- Co-author with S. El-Boustani, B.S. Sermet, G. Foustoukos, O. Yizhar, and C.C.H. Petersen, “Anatomically and Functionally Distinct Thalamocortical Inputs to Primary and Secondary Mouse Whisker Somatosensory Cortices,” 11(1) Nature Communications 3342, 2020
- Co-author with A. Wallach, D. Deutsch, and E. Ahissar, “Predictive Whisker Kinematics Reveal Context-Dependent Sensorimotor Strategies,” 18(5) PLoS e3000571, 2020
- Co-author with T.A. Zolnik, J. Ledderose, M. Toumazou, T. Trimbuch, C. Rosenmund, B.J. Eickholt, R.N.S. Sachdev, and M.E. Larkum, “Layer 6b is Driven by Intracortical Long-Range Projection Neurons,” 30(10) Cell Reports 3492-3505.e5, 2020
- Co-author with B.S. Sermet, P. Truschow, M. Feyerabend, J.M. Mayrhofer, O. Yizhar, J.F. Staiger, and C.C.H. Petersen, “Pathway-, Layer-and Cell-Type-Specific Thalamic Input to Mouse Barrel Cortex,” 8 eLife e52665, 2019
- Co-author with D. Sherman, D. Harel, and E. Ahissar, “Attention Robustly Gates a Closed-Loop Touch Reflex,” 27(12) Current Biology 1836-1843.e7, 2017
- Co-author with E. Ahissar, “Thalamic Relay or Cortico-Thalamic Processing? Old Question, New Answers,” 25(4) Cerebral Cortex 845-848, 2015
- Co-author with D. Sherman, D. Deutsch, G. Gordon, E. Ahissar, D. Harel, “Tactile Modulation of Whisking via the Brainstem Loop: Statechart Modeling and Experimental Validation,” 8(11) PLoS One e79831, 2013
Biological Sciences and Biotechnology
- Biophysics
- Neurobiology
- Virology
Therapeutics and Drug Discovery
- CRISPR
- Drug delivery
- Gene editing
- Gene therapy
- Neuropharmacology
Diagnostics and Medical Devices
- Bioinformatic
- Biomedical devices
- Biomedical engineering
- Biosensors
- Medical devices
- Medical imaging
- Neuroimaging
- Telemedicine technology
- Wearable analyte sensors
Engineering and Technology
- Machine learning
Genomics and Data Analysis
- Bioinformatics algorithms
- Computational biology
- Next-generation sequencing
- Sequencing
- Single-cell sequencing
Miscellaneous
- Biostatistics in clinical trials
- Fluorescence microscopy
- Litigation/PTAB/Oppositions
- Physiology
- Psychology
Technical Fluency
Biological Sciences and Biotechnology
- Biophysics
- Neurobiology
- Virology
Therapeutics and Drug Discovery
- CRISPR
- Drug delivery
- Gene editing
- Gene therapy
- Neuropharmacology
Diagnostics and Medical Devices
- Bioinformatic
- Biomedical devices
- Biomedical engineering
- Biosensors
- Medical devices
- Medical imaging
- Neuroimaging
- Telemedicine technology
- Wearable analyte sensors
Engineering and Technology
- Machine learning
Genomics and Data Analysis
- Bioinformatics algorithms
- Computational biology
- Next-generation sequencing
- Sequencing
- Single-cell sequencing
Miscellaneous
- Biostatistics in clinical trials
- Fluorescence microscopy
- Litigation/PTAB/Oppositions
- Physiology
- Psychology
Focus Areas
Recent Insights
Client Highlights
Wilson Sonsini Advises Think Bioscience on Patent Matters Related to Oversubscribed $55 Million Series A
On January 20, 2026, Think Bioscience (Think Bio), a Boulder-based biotechnology company focused on unlocking elusive drug targets, has raised $55 million in an oversubscribed Series A. The round was led by Regeneron Ventures, Innovation Endeavors, and Janus Henderson Investors with participation from T.A. Springer, CE-Ventures, MBX Capital, and YK Bioventures. Returning investors include AV8 Ventures, CU Innovations, and Buff Gold Ventures. Wilson Sonsini Goodrich & Rosati advised Think Bio on patent matters related to the transaction.
Learn More
Client Highlights
Firm Advises Evidity on IP Matters Related to GT MedTech’s $37 Million Series D
On January 16, 2025, GT Medical Technologies, Inc. (GT MedTech), a medical device company with a corporate purpose of improving the lives of patients with brain tumors, announced that it has completed a $37 million first close of a Series D financing round. The financing was led by Evidity Health Capital, alongside new investor Accelmed Partners. Also participating were existing investors MVM Partners, Gilde Healthcare, and Medtech Venture Partners. Wilson Sonsini Goodrich & Rosati advised Evidity Health Capital on IP matters related to the transaction.
The funds will accelerate the completion of the ROADS clinical study that is focused on GammaTile for newly diagnosed brain metastases, and the GESTALT clinical trial for patients with newly diagnosed glioblastomas (GBMs). In addition, the funds will support the continued commercialization of GammaTile®, GT MedTech’s FDA-cleared bioresorbable radiotherapy implant for the treatment of brain tumors.
The Wilson Sonsini team that advised Evidity Health Capital on IP matters included Bill Barrett, Darby Chan, Karl Hudspith, Tess Oram, and Sarah Ko.
For more information, please see the news release.
The funds will accelerate the completion of the ROADS clinical study that is focused on GammaTile for newly diagnosed brain metastases, and the GESTALT clinical trial for patients with newly diagnosed glioblastomas (GBMs). In addition, the funds will support the continued commercialization of GammaTile®, GT MedTech’s FDA-cleared bioresorbable radiotherapy implant for the treatment of brain tumors.
The Wilson Sonsini team that advised Evidity Health Capital on IP matters included Bill Barrett, Darby Chan, Karl Hudspith, Tess Oram, and Sarah Ko.
For more information, please see the news release.
Learn More
- Privacy Policy
- Terms of Use
- Accessibility
Copyright © 2026 Wilson Sonsini Goodrich & Rosati. All Rights Reserved.